U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C3H3BrO3
Molecular Weight 166.958
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BROMOPYRUVATE

SMILES

OC(=O)C(=O)CBr

InChI

InChIKey=PRRZDZJYSJLDBS-UHFFFAOYSA-N
InChI=1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)

HIDE SMILES / InChI
Bromopyruvate is an halogenated analogue of pyruvic acid known as an alkylating agent reacting with thiol groups of many proteins. Bromopyruvate exerts anticancer action. It is based on the impairment of energy metabolism of tumor cells by inhibiting enzymes in the glycolysis pathway (hexokinase II, glyceraldehyde 3-phosphate dehydrogenase, phosphoglycerate kinase) and the oxidative phosphorylation (succinate dehydrogenase). Bromopyruvate induces endoplasmic reticulum stress, inhibits global protein synthesis further contributing to cancer cell death. Treatment with bromopyruvate has been administered in several cancer type models both in vitro and in vivo, either alone or in combination with other anticancer therapeutic approaches. These studies clearly demonstrate bromopyruvate broad action against multiple cancer types. This compound has also antifungal and antiparasitic activity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.67 µM [IC50]
Target ID: O00187|||Q9H498
Gene ID: 10747.0
Gene Symbol: MASP2
Target Organism: Homo sapiens (Human)
Target ID: GO:0045254 | pyruvate dehydrogenase complex
PubMed

PubMed

TitleDatePubMed
2-Methylisocitrate lyases from the bacterium Escherichia coli and the filamentous fungus Aspergillus nidulans: characterization and comparison of both enzymes.
2001 Jun
Modification of human erythrocyte pyruvate kinase by an active site-directed reagent: bromopyruvate.
2001 Nov
Investigation of red blood cell carbonic anhydrase, glucose 6-phosphate dehydrogenase, hexokinase enzyme activities, and zinc concentration in patients with hyperthyroid diseases.
2002 Feb-May
An absolute requirement of fructose 1,6-bisphosphate for the Lactobacillus casei L-lactate dehydrogenase activity induced by a single amino acid substitution.
2002 Jan
Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production.
2002 Jul 15
Lack of antifertility properties of novel halogenated glycolytic inhibitors and the urinary excretion and metabolism of 1,6-dichloro-1,6-dideoxy-D-fructofuranose in the male rat.
2002 Jun
Crystal structure of 2-methylisocitrate lyase (PrpB) from Escherichia coli and modelling of its ligand bound active centre.
2003 May 2
Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia.
2005 Jan 15
Synthesis of functionalized 5-imino-2,5-dihydro-furans through the reaction of isocyanides with activated acetylenes in the presence of ethyl bromopyruvate.
2006 Aug
Hepatic intra-arterial injection of 3-bromopyruvate in rabbit VX2 tumor.
2006 Dec
Inactivation of H+-vacuolar ATPase by the energy blocker 3-bromopyruvate, a new antitumour agent.
2006 Oct 19
[Expression of hexokinase-II gene in human colon cancer cells and the therapeutic significance of inhibition thereof].
2007 Apr 17
The cancer cell's "power plants" as promising therapeutic targets: an overview.
2007 Feb
Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer.
2007 Jan
Local toxicity of hepatic arterial infusion of hexokinase II inhibitor, 3-bromopyruvate: In vivo investigation in normal rabbit model.
2007 Jan
Cytometric assessment of DNA damage by exogenous and endogenous oxidants reports aging-related processes.
2007 Nov
Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells : ROS-mediated cell death by 3-BrPA.
2008 Dec
A novel strategy involved in [corrected] anti-oxidative defense: the conversion of NADH into NADPH by a metabolic network.
2008 Jul 16
Strategies for molecular imaging dementia and neurodegenerative diseases.
2008 Jun
Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model.
2008 Nov
Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study.
2008 Oct
A one-pot synthesis of functionalized thiazoles from acid chlorides, secondary amines, ethyl bromopyruvate, and ammonium thiocyanate.
2009 Aug
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death.
2009 Dec
Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.
2009 Feb
Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells.
2009 Feb 26
Senescence induction; a possible cancer therapy.
2009 Jan 8
Inhibitive effect of 3-bromopyruvic acid on human breast cancer MCF-7 cells involves cell cycle arrest and apoptotic induction.
2009 Jul 20
Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate.
2009 Oct 15
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.
2009 Sep 18
Role of the mitochondrion in programmed necrosis.
2010
The pyruvic acid analog 3-bromopyruvate interferes with the tetrazolium reagent MTS in the evaluation of cytotoxicity.
2010 Apr
3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy.
2010 Aug
Cancer as a metabolic disease.
2010 Jan 27
Glycolytic enzyme inhibitors affect pancreatic cancer survival by modulating its signaling and energetics.
2010 Mar
3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines.
2010 May 28
Analyzing the regulation of metabolic pathways in human breast cancer.
2010 Sep 10
Casiopeina II-gly and bromo-pyruvate inhibition of tumor hexokinase, glycolysis, and oxidative phosphorylation.
2012 May
MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors.
2013 Jan
Name Type Language
BROMOPYRUVATE
Systematic Name English
3-Bromo-2-oxo-propionic acid
Systematic Name English
β-Bromopyruvic acid
Common Name English
3-BROMOPYRUVATE
Common Name English
NSC-11731
Code English
3-Bromopyruvic acid
Systematic Name English
NSC-62343
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 894722
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
FDA ORPHAN DRUG 390013
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
FDA ORPHAN DRUG 430514
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
FDA ORPHAN DRUG 736920
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
Code System Code Type Description
PUBCHEM
70684
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
NSC
11731
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
WIKIPEDIA
Bromopyruvate
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
MESH
C017092
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
NSC
62343
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
EPA CompTox
DTXSID7040940
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
ECHA (EC/EINECS)
214-206-5
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
SMS_ID
100000177177
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
CAS
1113-59-3
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
FDA UNII
63JMV04GRK
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY